Department of Radiology, Stanford University School of Medicine, Stanford, California, USA.
J Magn Reson Imaging. 2024 Nov;60(5):2104-2114. doi: 10.1002/jmri.29279. Epub 2024 Feb 14.
Beta-catenin-mutated hepatocellular adenomas (β-HCAs) can appear iso- to hyperintense at the hepatobiliary phase (HBP) at magnetic resonance imaging (MRI). Given the relatively lower prevalence of β-HCAs, prior studies had limited power to show statistically significant differences in the HBP signal intensity between different subtypes.
To assess the diagnostic performance of HBP MRI to discriminate β-HCA from other subtypes.
Systemic review and meta-analysis.
Ten original studies were included, yielding 266 patients with 397 HCAs (9%, 36/397 β-HCAs and 91%, 361/397 non-β-HCAs).
FIELD STRENGTH/SEQUENCE: 1.5 T and 3.0 T, HBP.
PubMed, Web of Science, and Embase databases were searched from January 1, 2000, to August 31, 2023, for all articles reporting HBP signal intensity in patients with histopathologically proven HCA subtypes. QUADAS-2 was used to assess risk of bias and concerns regarding applicability.
Univariate random-effects model was used to calculate pooled estimates. Heterogeneity estimates were assessed with I heterogeneity index. Meta-regression (mixed-effect model) was used to test for differences in the prevalence of HBP signal between HCA groups. The threshold for statistical significance was set at P < 0.05.
HBP iso- to hyperintensity was associated with β-HCAs (pooled prevalence was 72.3% in β-HCAs and 6.3% in non-β-HCAs). Pooled sensitivity and specificity were 72.3% (95% confidence interval 54.1-85.3) and 93.7% (93.8-97.7), respectively. Specificity had substantial heterogeneity with I of 83% due to one study, but not for sensitivity (I = 0). After excluding this study, pooled sensitivity and specificity were 77.4% (59.6-88.8) and 94.1% (88.9-96.9), with no substantial heterogeneity. One study had high risk of bias for patient selection and two studies were rated unclear for two domains.
Iso- to hyperintensity at HBP MRI may help to distinguish β-HCA subtype from other HCAs with high specificity. However, there was heterogeneity in the pooled estimates.
3 TECHNICAL EFFICACY: Stage 2.
β-连环蛋白突变型肝细胞腺瘤(β-HCA)在磁共振成像(MRI)肝胆期(HBP)可表现为等信号至高信号。鉴于β-HCA 的相对较低患病率,先前的研究在统计上显示不同亚型之间 HBP 信号强度的差异方面的能力有限。
评估 HBP MRI 对鉴别β-HCA 与其他亚型的诊断性能。
系统评价和荟萃分析。
10 项原始研究共纳入 266 例患者,共 397 例 HCA(9%,36/397β-HCA 和 91%,361/397 非-β-HCA)。
场强/序列:1.5T 和 3.0T,HBP。
从 2000 年 1 月 1 日至 2023 年 8 月 31 日,通过 PubMed、Web of Science 和 Embase 数据库搜索所有报道 HCA 组织学亚型患者 HBP 信号强度的文章。采用 QUADAS-2 评估偏倚风险和适用性问题。
采用单变量随机效应模型计算汇总估计值。采用 I 异质性指数评估异质性估计值。采用混合效应模型进行荟萃回归(混合效应模型)以检验 HBP 信号在 HCA 组之间的差异。统计显著性阈值设为 P<0.05。
HBP 等至高信号与β-HCA 相关(β-HCA 中的汇总患病率为 72.3%,非-β-HCA 中的患病率为 6.3%)。汇总敏感性和特异性分别为 72.3%(95%置信区间 54.1-85.3)和 93.7%(93.8-97.7)。由于一项研究,特异性存在很大的异质性(I=83%),但敏感性没有(I=0)。排除该研究后,汇总敏感性和特异性分别为 77.4%(59.6-88.8)和 94.1%(88.9-96.9),异质性较小。一项研究在患者选择方面存在高偏倚风险,两项研究在两个领域的评价不明确。
HBP MRI 的等至高信号可能有助于高特异性地区分β-HCA 亚型与其他 HCA。然而,汇总估计值存在异质性。
3 级。技术效能:2 级。